Monitoring

FDA approval now means critical glucose data from the Dexcom G4® PLATINUM Continuous Glucose Monitoring System can be remotely monitored using a mobile device

BD is to acquire CareFusion for $12.2 billion, to create a global leader in medication management and patient safety solutions.

Staring down the barrel, standing on the brink. Call it what you like, but events have overtaken Echo Therapeutics’ efforts to keep the door open. Failing a last minute solution things look bad for the wireless glucose monitoring technologists.

Diagnostic and Monitoring company EXALENZ Bioscience has been named as one of the prestigious Deloitte Technology Fast 50, an annual ranking of the 50 fastest-growing technology companies in Israel for 2014.

ResMed’s Air Solutions platform has data-driven components that span from diagnosis to treatment, compliance management and patient engagement.

Molecular diagnostics company Transplant Genomics Inc. has obtained an exclusive license to patent rights that provide the foundation for clinical tests to improve management of organ transplant recipients.

Israeli device company Itamar Medical has reported the U.S. FDA clearance of its new and upgraded WatchPAT™ Unified sleep apnea diagnostic device.

The U.S. FDA has cleared Edwards’ ClearSight system, a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications

Continuous Glucose Monitoring (CGM) device company Dexcom, Inc., has received U.S. FDA approval for its Dexcom G4® PLATINUM Professional CGM.

Echo Therapeutics, with its clever continuous glucose monitoring technology, is beset with woes coming mainly, so it seems from one dissident 20% shareholder. Now Echo’s board has written to shareholders questioning Platinum Group’s agenda in waging a costly and distracting proxy contest.

Recommends Stockholders Vote Revised White Proxy Card

It’s been stormy waters for Echo Therapeutics during 2013, a year that saw cash dwindling, shareholder angst and boardroom changes, before new money arrived and cost-cutting measures started to turn the ship around.

Remote monitoring of ICDs has been shown to improve patient adherence to follow-up regimes when compared with traditional repeat check-up appointments. It’s surely the biggest “no-brainer” the specialty has seen for years.

Frequent visitor to our pages, cardiovascular device company Biotronik has announced the first implantations of the Sentus ProMRI® lead.

Biotronik is pointing to new study data showing that use of its Biotronik Home Monitoring® system has saved the French National Health Insurance system costs, in addition to being safe and efficient.

As financial pressures mount, automated bedside patient monitoring should really provide reassurance that patient care won’t drop through the cracks. New enhancements to the EarlySense system deliver more monitoring options, including respiration, heart rate and motion.

Echo Therapeutics will receive a $10 million cash investment from MTIA and Platinum Partners as part of a new strategic collaboration that will see its interests in a chunk of the Far East devolved to MTIA.